tiprankstipranks
Morning Movers: Viridian and Edgewise jump following successful trials
PremiumThe FlyMorning Movers: Viridian and Edgewise jump following successful trials
9d ago
Viridian Therapeutics Achieves Milestone in Phase 3 Trial
Premium
Company Announcements
Viridian Therapeutics Achieves Milestone in Phase 3 Trial
9d ago
Viridian Therapeutics announces THRIVE-2 trial met primary, secondary endpoints
Premium
The Fly
Viridian Therapeutics announces THRIVE-2 trial met primary, secondary endpoints
9d ago
Viridian Therapeutics Advances in Biotech Innovations
PremiumCompany AnnouncementsViridian Therapeutics Advances in Biotech Innovations
1M ago
Viridian Therapeutics reports Q3 EPS ($1.15), consensus ($1.06)
Premium
The Fly
Viridian Therapeutics reports Q3 EPS ($1.15), consensus ($1.06)
1M ago
Is VRDN a Buy, Before Earnings?
Premium
Pre-Earnings
Is VRDN a Buy, Before Earnings?
2M ago
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
3M ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
3M ago
Viridian Therapeutics price target raised to $44 from $35 at RBC Capital
Premium
The Fly
Viridian Therapeutics price target raised to $44 from $35 at RBC Capital
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100